Treatment preferences of adolescent patients with asthma
- 1 February 2000
- journal article
- clinical trial
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 11 (1) , 49-55
Abstract
The study objective was to assess whether asthmatic adolescents who were regular users of inhaled corticosteroids preferred treatment with zafirlukast tablets or inhaled beclomethasone dipropionate (BDP), and, secondarily, to assess adolescents’ inhaler technique and their opinions about treatment. An open‐label, randomized, two‐period, cross‐over study was conducted in 18 centres (primary care to specialist asthma centres) in South Africa, the UK, Finland and the Czech Republic. One hundred and thirty‐two adolescents aged 12–17 years with asthma for at least 1 year and FEV1 ≥ 75% of predicted, treated with short‐acting bronchodilators and inhaled corticosteroids, entered the study. Patients received oral zafirlukast tablets (Accolate™) 20 mg bd or inhaled BDP 100 or 200 µg bd, provided by a standard pressurized metered‐dose inhaler, for 4 weeks each. One questionnaire was used to determine preference (the primary outcome measure) and a second questionnaire was used to determine patients’ likes and dislikes of treatment. Investigators also scored inhaler technique. Of 113 adolescents, 79 (70%) preferred zafirlukast compared with 31 (27%) who preferred the BDP inhaler (p < 0.001); three had no preference. Only 35 (29%) of 122 adolescents could use their inhaler correctly at study entry. Seventy‐six patients (65%) rated zafirlukast tablets as ‘very easy’ to use, compared with 35 (30%) for the BDP inhaler. Both treatments were well tolerated. This study shows that asthmatic adolescents prefer zafirlukast tablets by a ratio of 2.6:1 over inhaled BDP, and these results may have implications for improving adolescent patient compliance with asthma therapy.Keywords
This publication has 16 references indexed in Scilit:
- Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction☆☆☆★★★♢Journal of Allergy and Clinical Immunology, 1998
- Population based study of risk factors for underdiagnosis of asthma in adolescence: Odense schoolchild study Commentary: Risk factors for underdiagnosis of asthma in adolescence Commentary: Identifying the correct risks in diagnosis Commentary: Improving the diagnostic rate in asthma: a community issueBMJ, 1998
- Prevalence of asthma symptoms, diagnosis, and treatment in 12–14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK)BMJ, 1998
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- Noncompliance and treatment failure in children with asthmaJournal of Allergy and Clinical Immunology, 1996
- Parents' perceptions towards their child's use of inhaled medications for asthma therapyJournal of Paediatrics and Child Health, 1996
- Oral vs Inhaled Asthma TherapyDrugs, 1996
- Effects of 6 Weeks of Therapy with Oral Doses of ICI 204,219, a Leukotriene D4 Receptor Antagonist, in Subjects with Bronchial Asthma. ACCOLATE Asthma Trialists GroupAmerican Journal of Respiratory and Critical Care Medicine, 1994
- Trends in prevalence and severity of childhood asthmaBMJ, 1994
- Comparison of Bricanyl® Turbuhaler and Berotec® dry powder inhalerAllergy, 1990